Shopping cart

Subtotal: ₨ 35

Checkout View Cart

Home
Checkout
Shop
0Wishlist

Delivering All Over Pakistan

+92 344 1054239

My Wishlist

Recently Viewed

You have no recently viewed item.
  1. Home
  2. Medicines
  3. Anti Diabetics
Prev
XODERON 8MG INJ - ChemistCart
XODERON 8MG INJ ChemistCart₨ 300 / per unit
Next
XYLOAID JELLY₨ 67 / per unit
XYLOAID JELLY 15g - ChemistCart
XULTOPHY- ChemistCart

XULTOPHY 100UNITS/3ML

₨ 10,072 / per unit

XULTOPHY- ChemistCart

₨ 10,072 / per unit

Add to cart
Buy Now
Categories: Brand:

Generics

Insulin degludec + Liraglutide

Used For

Diabetes Management

How it works

XULTOPHY 100/3.6 is a combination product consisting of insulin degludec and liraglutide. Insulin degludec : The primary activity of insulin degludec is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis. Liraglutide : Liraglutide is a GLP-1 receptor agonist that increases glucosedependent insulin release, decreases glucagon secretion, and slows gastric emptying .

Usage And Safety

Dosage

Adults : Once daily via SC route . Can be administered at any time of the day , preferably at the same time of the day . Administered as dose steps . One dose step contains 1 unit of insulin degludec and 0.036mg of liraglutide . Max daily dose is 50 dose steps . Add-on to oral glucose-lowering medicinal products : The recommended initial dose is 10 dose steps . When added to sulfonylurea therapy , a reduction in the dose of sulfonylurea should be considered . Transfer from basal insulin : Therapy with GLP-1 rec agonists should be discontinued prior to initiation of Xultropy . The recommended initial dose is 16 dose steps . Close glucose monitoring is required during the transfer and in following weeks . Or as directed by your physician .

Side Effects

Hypoglycaemia , nausea , diarrhoea , vomiting , constipation , dyspepsia , gastritis , abdominal pain , GERD , abdominal distension , inj-site reaction .

Drug Interactions

Pioglitazone (discontinue). MAOIs , beta-blockers , ACE inhibitors , salicylates , anabolic steroids , sulfonamides . Oral contraceptives , thiazides , glucocorticoids , thyroid hormones , sympathomimetics , growth hormones , danazol , octreotide . Lanreotide.

Indication

Xultophy 100/3.6 (insulin degludec and liraglutide) injection 100 units/mL and 3.6 mg/mL is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Top
Top